Clinical Trial

Study of XNW5004 Tablets in Advanced Prostate Cancer

Study acronym: XNW5004 Tablet
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase Ib A preliminary design of 2 cohorts is planned for this phase, with 3-6 participants to be enrolled in each cohort. A total of 6-12 participants with advanced prostate cancer are planned to be enrolled in this phase. The study will be conducted at multiple investigational sites. Phase II A preliminary design of 5 cohorts is planned for this phase. Cohorts 1, 2, and 3 are preset with 2 dose groups each, and each dose group plans to enroll 20-30 participants. Cohort 4 plans to enroll 20-50 participants. Cohort 5 will be adjusted based on results from prior study phases. A total of 140-230 participants with advanced prostate cancer are planned to be enrolled in this phase. The study will be conducted at multiple investigational sites.
Trial Details
NCT Number NCT07730580
Lead Sponsor Evopoint Biosciences Inc.
Conditions Advanced Prostate Cancer
Enrollment 242 participants
Start Date 2026-07-13
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28